Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin‐6 and β₂‐microglobulin in multiple myeloma

Abstract

These results suggest that a monthly dose of 90 mg of pamidronate is more effective than 4 mg of ibandronate in reducing osteoclast activity, bone resorption, IL-6, and possibly tumour burden in MM. TRACP-5b has also proved to be a useful new marker for monitoring bisphosphonates treatment in MM.